These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36289682)

  • 1. Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas.
    Atar D; Mast AS; Scheuermann S; Ruoff L; Seitz CM; Schlegel P
    Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.
    Seitz CM; Mittelstaet J; Atar D; Hau J; Reiter S; Illi C; Kieble V; Engert F; Drees B; Bender G; Krahl AC; Knopf P; Schroeder S; Paulsen N; Rokhvarguer A; Scheuermann S; Rapp E; Mast AS; Rabsteyn A; Schleicher S; Grote S; Schilbach K; Kneilling M; Pichler B; Lock D; Kotter B; Dapa S; Miltenyi S; Kaiser A; Lang P; Handgretinger R; Schlegel P
    Oncoimmunology; 2021; 10(1):2003532. PubMed ID: 35686214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
    Torres-Collado AX; Jazirehi AR
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29904021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting.
    Grote S; Mittelstaet J; Baden C; Chan KC; Seitz C; Schlegel P; Kaiser A; Handgretinger R; Schleicher S
    Oncoimmunology; 2020 Sep; 9(1):1825177. PubMed ID: 33457105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.
    Atar D; Ruoff L; Mast AS; Krost S; Moustafa-Oglou M; Scheuermann S; Kristmann B; Feige M; Canak A; Wolsing K; Schlager L; Schilbach K; Zekri L; Ebinger M; Nixdorf D; Subklewe M; Schulte J; Lengerke C; Jeremias I; Werchau N; Mittelstaet J; Lang P; Handgretinger R; Schlegel P; Seitz CM
    Leukemia; 2024 Oct; 38(10):2183-2195. PubMed ID: 39095503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Yin Z; Zhang Y; Wang X
    Biomark Res; 2021 Jul; 9(1):58. PubMed ID: 34256851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
    Köksal H; Dillard P; Josefsson SE; Maggadottir SM; Pollmann S; Fåne A; Blaker YN; Beiske K; Huse K; Kolstad A; Holte H; Kvalheim G; Smeland EB; Myklebust JH; Inderberg EM; Wälchli S
    Blood Adv; 2019 Apr; 3(8):1230-1243. PubMed ID: 30979721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
    Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
    J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
    Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H
    Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cell therapy for B-cell lymphoma.
    Denlinger N; Bond D; Jaglowski S
    Curr Probl Cancer; 2022 Feb; 46(1):100826. PubMed ID: 35012754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.
    Benevolo Savelli C; Clerico M; Botto B; Secreto C; Cavallo F; Dellacasa C; Busca A; Bruno B; Freilone R; Cerrano M; Novo M
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas.
    Ding S; Mao X; Cao Y; Wang N; Xu H; Zhou J
    Target Oncol; 2020 Jun; 15(3):365-375. PubMed ID: 32495161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
    Du J; Zhang Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma.
    Giraudo MF; Jackson Z; Das I; Abiona OM; Wald DN
    Pathog Immun; 2024; 9(1):1-17. PubMed ID: 38550613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
    Fousek K; Watanabe J; Joseph SK; George A; An X; Byrd TT; Morris JS; Luong A; Martínez-Paniagua MA; Sanber K; Navai SA; Gad AZ; Salsman VS; Mathew PR; Kim HN; Wagner DL; Brunetti L; Jang A; Baker ML; Varadarajan N; Hegde M; Kim YM; Heisterkamp N; Abdel-Azim H; Ahmed N
    Leukemia; 2021 Jan; 35(1):75-89. PubMed ID: 32205861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.
    Schneider D; Xiong Y; Wu D; Hu P; Alabanza L; Steimle B; Mahmud H; Anthony-Gonda K; Krueger W; Zhu Z; Dimitrov DS; Orentas RJ; Dropulić B
    Sci Transl Med; 2021 Mar; 13(586):. PubMed ID: 33762438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
    Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
    Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.